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Thakker D., Nair S.R., Shukla H, Shaikh J.S.
Capita India Pvt. Ltd., Mumbai, India
Objectives: Statins are widely used for the primary and secondary prevention 
of cardiovascular diseases (CVDs). Studies have shown that statins may induce 
diabetes in non-diabetic CVD patients, as class effect. This systematic literature 
review aims to evaluate the risk of developing diabetes in CVD patients receiving 
statins. MethOds: Randomized controlled trials (RCTs), which used any statin as 
an intervention for non-diabetic CVD patients, were identified from August 2010 
to June 2014 in databases such as, Embase, PubMed, and Cochrane. The timeframe 
of the searches was selected post the study conducted by Mills et al. in 2011. This 
review will also include relevant studies from the Mills et al. study until August 2010. 
Two researchers will independently review studies as per the Cochrane method-
ology for systematic reviews. The primary outcome is the incidence of diabetes. 
Subgroup analyses will also be performed to assess whether statin type, age, eth-
nicity or patient groups contribute to the intensity of the risk of developing dia-
betes. Results: In total, 5238 potentially relevant studies were retrieved from the 
databases and are being screened for inclusion in the review. The data extraction 
and analyses (both qualitative and quantitative) are being performed and the full 
results will be presented in the poster. cOnclusiOns: This systematic literature 
review is an update of the findings of a previous study and will hopefully throw 
more light on the association between statin use and the risk of diabetes in CVD 
patients, with special emphasis on subgroups.
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Objectives: The aim of this retrospective cohort study was to calculate hazard 
rates of CV/non-CV related death in risk patients stratified by statin dose and to 
generate data for health-economic analyses. MethOds: Anonymous retrospective 
electronic medical records were extracted from a 10% sample of the Swedish popula-
tion > 18 years in primary care and merged with hospital records, prescribed drugs, 
and death data by National Board of Health and Welfare. Cohorts were defined as 
diabetic (DM), Clinically-evident CardioVascular Disease (CeCVD), Acute Coronary 
Syndrome (ACS), Heart Failure (HF) and Ischemic Stroke (IS) patients. CV/non-CV 
related death was investigated. The population was divided into high dose statin 
users (> 40 mg simvastatin or equivalent) and non-statin users. Royston Parmar (RP) 
spline analysis was used to calculate hazard rates of both outcomes in each cohort 
to enable a smooth hazard function with good fit to data compared to ordinary Cox 
regression. Initial AIC-based optimization demonstrated that modeling of the log 
cumulative odds as a spline function of log time and three nodes gave the best fit. 
Crude rates were calculated for each cohort and event, and hazard rates adjusted 
for gender, diabetes, LDL (where applicable) and age were calculated. Results: 
The total database consisted of 1.3 million patients; there were 55,778 DM, 47,581 
CeCVD, 49,857 ACS, 82,835 HF and 38,949 IS patients. High dose statin users showed 
after initial decrease a constant/marginally increasing hazard rate, whereas the no 
statin group after initial decrease had a strong increase in hazard rate versus time. 
The overall hazard rate was always higher for the no statin group. Independent of 
statin status diabetics and males demonstrated an at least numeric elevated hazard 
rate. cOnclusiOns: RP splines could be used to generate hazard rate functions 
for cost-effectiveness models. The death rate was lower in patients with high dose 
statin usage.
CaRdiOVaSCUlaR diSORdeRS – Cost Studies
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Objectives: Varenicline is indicated for smoking cessation. Around 60.000 peo-
ple die every year in Spain because of tobacco related diseases, particularly car-
diovascular diseases (CVD), chronic obstructive pulmonary disease (COPD) and 
type-2 diabetes mellitus (t2DM). At present, varenicline is not reimbursed in the 
Spanish National Health System (NHS). The objective was to estimate the budgetary 
impact (BI) for the NHS of the reimbursement of varenicline in smoking cessation 
in patients with CVD, COPD or t2DM. MethOds: BI was estimated comparing the 
actual not-reimbursed scenario versus a reimbursed scenario using the Spanish 
NHS perspective. A hybrid BI model was designed using epidemiological data to 
estimate size of populations and a Markov modelling simulating until four quit-
ting attempts to estimate smoking cessation rates with varenicline during a 5-year 
horizon. Costs of cessation attempts were considered in the reimbursement sce-
nario only, and included varenicline, medical visits and counselling. Effectiveness 
of varenicline was expressed as one year of abstinence rate following a 12-weeks 
course of standard doses, and were derived from clinical trials. Cost savings due to 
smoking cessation were extracted from local published cost-of-illness studies in 
such populations. Results showed incremental cost-savings of reimbursed versus 
not reimbursed scenario. Univariate sensitivity analysis was also applied. Results: 
Five-years cumulated cessation attempts increased from 140,795 in the not-reim-
bursed to 354,631 in the reimbursed scenario, yielding to 52,127 extra subjects 
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Objectives: Evidence suggests an association between dental disease and car-
diovascular disease (CVD). C-reactive protein (CRP), an inflammatory marker, has 
been implicated as a risk factor for CVD, and dental disease can affect CRP levels. 
Our study examined the relationship between the timing and nature of dental 
visits and CRP. MethOds: Using data from the US-based 1999-2000, 2001-2002, 
and 2003-2004 National Health and Nutrition Examination Surveys, we examined 
the relationship between time since and reason for most recent dental visit and 
CRP among adults ≥ 20 years old. Participants were excluded if they were pregnant 
at the time of the survey, did not take part in the examination component of the 
survey, or were missing covariates for a logistic regression model: age, sex, race, 
BMI, HbA1c, WBC count, CRP measure, time since and reason for last dental visit, 
smoking status, cholesterol-lowering medication use, and history of asthma, cancer, 
rheumatoid arthritis, chronic bronchitis, or recent illness. A dichotomous elevated 
CRP measure was used, defined as CRP > 0.30 mg/dL. Time since last dental visit 
was categorized as < 6 months, 6 months to < 1 year, 1 year to < 2 years, and 2+ 
years ago; respondents who reported never visiting a dentist were placed in the 
2+ years category. Results: A greater proportion of the normal (≤ 0.30 mg/dL) CRP 
group last visited a dentist < 6 months ago (P= 0.0460), and last visited the dentist 
for a “preventive” visit (P< 0.0001), while a greater proportion of the elevated CRP 
group last visited the dentist for a “symptom-driven” visit (P< 0.0001). Regression 
model results demonstrated that preventive visits are associated with a reduced 
likelihood of elevated CRP (OR= 0.722; P= 0.0120), regardless of the time since last 
visit. cOnclusiOns: Given the apparent association between risk of elevated CRP 
and reason for the last dental visit, medical and dental providers should consider 
interventions specifically around appropriate dental care.
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Objectives: A systematic literature review of longitudinal studies across a broad 
range of both general and disease specific populations was performed to understand 
characteristics of patients with type 2 diabetes (T2D) with risk factors for cardiovas-
cular (CV) events and whether the magnitude of CV risk varies across different T2D 
populations. MethOds: MeSH term based literature searches were performed in 
the PubMed, EMBASE and Cochrane Library databases. For inclusion, studies (in any 
disease area) were required to have a minimum of 1,000 T2D patients and minimum 
5 years follow up. After 2 rounds of review a total of 52 articles and 2 meta-analyses 
were included. Results: Twenty nine articles were described as prospective studies; 
13 articles were from Europe, 20 from Asia Pacific, 13 from North America, 2 from the 
Middle East and 4 were multinational. Six articles were sourced from general or non-
diabetes specific data and 46 articles were based on diabetes studies. Several publica-
tions were from large scale diabetes registries (e.g. Hong Kong Diabetes Registry [n= 6] 
and the Swedish National Diabetes Register [n= 4]). The review also identified several 
post-hoc analyses from clinical trials and large scale retrospective observational/
database analyses. Risk factors investigated included well characterized markers in 
T2D patients (e.g. HbA1c, blood pressure, lipids, proteinuria [n= 20]), less well char-
acterized factors including dietary components (n= 7), biochemical measures (e.g. 
serum uric acid, fibrinogen; n= 6), depression (n= 6) and poorly characterized risk 
factors including oral health (n= 1), erectile dysfunction (n= 1) and presence of H. pylori 
(n= 1). cOnclusiOns: Analysis of the literature showed that in addition to traditional 
risk markers, factors such as depression, erectile dysfunction, poor oral health are also 
independent risk factors for CV disease. These factors should be taken into account 
when estimating the CV risk profile for patients with T2D.
PCV31
RelatiOn Of the time in theRaPeUtiC Range (ttR) Of waRfaRin tO 
bleeding inCidenCeS in PatientS with atRial fibRillatiOn
Jasmi M.A.S.1, Mazlan M.N.1, Shaharuddin S.1, Zulkifly H.H.1, Long C.M.1, Hashim R.2, Abdul 
Wahab M.S.1
1Universiti Teknologi MARA, Selangor, Malaysia, 2Cyberjaya University College of Medical 
Sciences, Cyberjaya, Malaysia
Objectives: Warfarin use in atrial fibrillation has been established for preventing 
occurrence of stroke in patients with atrial fibrillation. However, safety and clinical 
monitoring of warfarin use is crucial due to its risk of bleeding complications. This 
study aims to compare and establish relation of time in therapeutic range (TTR) of 
warfarin in patients with atrial fibrillation in the first 6 months and 6 month thereaf-
ter of anticoagulation therapy. MethOds: This is a retrospective study carried out at 
a tertiary-care hospital with anticoagulation clinic in the state of Selangor, Malaysia. 
Data collected included patients’ demographics, co-morbidities, and international 
normalized ratio (INR). TTR were determined using Rosendaal method based on 
records found in database (INR Desk 4.0 system) and patients’ hemorrhage events 
were also recorded. Samples of the study were patient who started warfarin from 
January 2009 until March 2013. Results: A total of 167 patients with atrial fibrilla-
tion were enrolled and only 6% (n= 10) achieved TTR of more than 75% for the first 
6 months of warfarin use as compared to 16.8% (n= 28) of TTR more than 75% 6 
months thereafter. As for bleeding incidences, 29% (n= 45) of patients in the group 
of TTR less than 75% in the first 6 months had bleeding complications as compared 
to 18.7% (n= 26) in patients of TTR less than 75% 6 months after. cOnclusiOns: 
A more regular follow up is necessary during the first 6 months of new warfarin 
users as they tend to be out of the TTR and have a higher bleeding risk.
